This was the stock's second consecutive day of gains.

The data may change how patients are treated following a diagnosis for advanced triple-negative breast cancer, one expert ...

Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, ...

Jefferies analyst Michael Yee reaffirmed a Buy rating on Gilead Sciences Inc. (NASDAQ:GILD), maintaining his price target at ...

Gilead's HIV drug lenacapavir earns FDA priority review after strong trial results, with the company planning to double U.S.

J&J has a multi-year head start, but Gilead believes it can win market share by delivering a drug with better safety and at ...

A Gilead Sciences-backed therapy made with a patient's own white blood cells shrank tumors in 62% of patients with recurrent ...

FA new injection to prevent HIV is expected to be approved by the U.S. Food and Drug Administration (FDA) later this month.

Spoiler alert! Here's how Hulu's "The Handmaid's Tale" ends after six long seasons of June (Elisabeth Moss) in Gilead.

With a market cap of around $136 billion, Gilead Sciences, Inc. (GILD) is a biopharmaceutical company. The Foster City, ...

Gilead Sciences is well-positioned to continue to strengthen its position as a leader in the HIV therapy market. Learn more ...